Share Dilution From Stock Options
First written in FY2016. 4 of 14 entries say "Worsened", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
20 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Resolution date: 9 May 2022; common shares: 280,000; resolution date: 28 September 2022; common shares: 90,000」
Stock acquisition rights covering 280,000 and 90,000 shares for directors and employees remain outstanding, and the potential for future dilution continues to be disclosed. - FY2025RestatedAnnual report
「Common shares 280,000」
Stock acquisition rights covering 280,000 and 90,000 shares granted in 2022 remain outstanding, and the potential for future dilution continues. - FY2023Reversal gain on existing stock acquisition rights and outstanding new rightsAnnual report
「Gain on reversal of stock acquisition rights － 47,515」
The Company recognized a ¥47,515 thousand gain on reversal of stock acquisition rights due to their non-exercise. Meanwhile, stock acquisition rights covering 280,000 shares granted in May 2022 and 90,000 shares granted in September 2022 remain outstanding. - FY2023-Q2Cancellation of existing stock acquisition rights and new grantsAnnual report
「Granted on 19 October 2018: stock options; number of stock acquisition rights: 1,200 units (number of common shares: 120,000). All of the above stock acquisition rights were acquired and cancelled as of 24 October 2022. Granted on 19 October 2022: stock options; number of stock acquisition rights: 900 units (common shares: 90,000).」
While all 120,000 shares covered by the rights granted in 2018 were acquired and cancelled, stock acquisition rights covering 90,000 shares granted in 2022 were disclosed, replacing the potential dilution exposure. - FY2023-Q1MitigatedAnnual report
「These stock acquisition rights were issued to motivate the Company's directors and employees to improve performance, secure talented personnel and contribute to increasing corporate value. The holders of the stock acquisition rights have now requested to waive their rights, and the Company will acquire the waived stock acquisition rights without consideration and cancel them, causing the stock acquisition rights to cease to exist.」
All 120,000 stock acquisition rights covering shares granted in 2018 will be cancelled, reducing the potential dilution from existing rights. Separately, stock acquisition rights covering 90,000 shares pursuant to the resolution of 28 September 2022 have been disclosed. - FY2022WorsenedAnnual report
「The limit is 90,000 of the Company's common shares, of which the limit for common shares allotted to the Company's directors, excluding outside directors, is 60,000 shares.」
In connection with the shareholders' meeting held on 28 September 2022, an additional issuance capacity for stock acquisition rights covering up to 90,000 common shares was established, increasing the potential for future dilution. - FY2022-Q3WorsenedAnnual report
「280,000 of the Company's common shares (100 shares per stock acquisition right)」
Pursuant to a resolution of the Board of Directors dated 9 May 2022, the Company decided to issue paid stock acquisition rights covering 280,000 shares to 4 directors, increasing the potential for future share dilution. The scheduled allotment date is 26 May 2022. - FY2021MitigatedAnnual report
「Of the 140,000 shares outstanding at the end of the previous consolidated fiscal year, 10,000 shares expired, leaving 130,000 shares outstanding.」
The number of potential shares underlying the stock options decreased from 140,000 to 130,000. The exercise period from 27 September 2022 to 26 September 2028 was also disclosed. - FY2019-Q2RestatedAnnual report
「Granted on 19 October 2018 Stock options Number of common shares underlying the stock acquisition rights: 140,000 shares」
This reiterates the existence of stock acquisition rights granted on 19 October 2018 covering 140,000 common shares. - FY2019-Q1WorsenedAnnual report
「Number of stock acquisition rights (units) 1,400 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares) * Common shares 140,000 (Note 1)」
Based on the resolution of 27 September 2018, stock acquisition rights covering 140,000 common shares were granted on 19 October 2018, giving concrete form to the potential for future dilution. - FY2018WorsenedAnnual report
「The Company resolved to submit to its 20th annual general meeting of shareholders, held on 27 September 2018, a proposal seeking approval to issue stock acquisition rights as stock options to the Company's directors and employees. The proposal was approved at the meeting.」
Although the existing stock acquisition rights had been exhausted by the previous fiscal year, the issuance of stock acquisition rights for up to 300,000 shares, including a limit of 90,000 shares for directors, was approved, creating the potential for future dilution again. - FY2017MitigatedAnnual report
「The 360,000-share decrease in the number of treasury common shares resulted from the exercise of stock options.」
All 360,000 outstanding stock options were exercised, leaving no unexercised stock acquisition rights. Dilution from the exercise actually occurred. - FY2017-Q3MaterialisedAnnual report
「During the cumulative third quarter, the Company disposed of treasury shares upon the exercise of stock acquisition rights. Treasury shares decreased by ¥126,000 thousand and capital surplus increased by ¥23,139 thousand.」
Treasury shares were actually disposed of upon the exercise of stock acquisition rights, resulting in an event involving potential shares. - FY2016First statedAnnual report
「As of the end of the fiscal year, the total number of potential shares represented by share acquisition rights was 360,000. If these share acquisition rights are exercised, the value per share of our common stock may be diluted.」
The company discloses the number of potential shares and explains the potential dilution from exercising share acquisition rights.